摘要
目的构建以恶性疟原虫红内期重要的疫苗候选抗原——裂殖子表面蛋白１（ＭＳＰ１）羧基端编码分子量４２０００蛋白的基因片段为外源基因的可用作候选核酸疫苗的真核表达载体。方法目前对疟疾核酸疫苗的研究仅见于鼠疟，将恶性疟原虫ＦＵＰ株裂殖子表面蛋白１羧基端编码４２０００蛋白的基因片段用常规分子克隆方法，分别克隆入非分泌性真核表达载体ＶＲ１０１２和改建后的分泌型载体ＶＲ１０１２／ＴＰＡ中，通过ＰＣＲ和酶切鉴定出重组克隆。结果成功地构建了真核表达载体ＶＲ１０１２／ＭＳＰ１－４２和ＶＲ１０１２／ＴＰＡ／ＭＳＰ１－４２。结论目前对疟疾核酸疫苗的研究仅见于鼠疟红外期，该研究对研制有效的恶性疟原虫红内期核酸疫苗是一个有益的尝试。其免疫保护作用待进一步研究。
Objectives Nucleic acid vaccine has several major advantages over other types of available vaccines,such as in situ eukaryotic expression and generation of extensively cellular response.To construct a couple of eukaryotic expression recombinants containing the gene fragment of C terminal region (coding for 42kD protein) of Plasmodium falciparum(P.f) merozoite surface protein 1(MSP1),which could be a candidate nucleic acid vaccine. Methods The gene fragment of C terminal region (coding for 42kD protein) of MSP1 from P.f FUP strain was cloned into eukaryotic expression plasmid VR1012 for intracellular expression and VR1012/TPA for secretion by commonly used molecular clone methods.The eukaryotic expression recombinants were identified by PCR and restriction enzyme.Results The recombinants VR1012/MSP1 42 and VR1012/TPA/MSP1 42 were successfully constructed.Conclusions\ Up to now only nucleic acid vaccine of rodent malaria was reported.This study provides a good basis for us to find out an effective P.f erythrocytic stage nucleic acid vaccine .The protective immune response to these vaccines will be studied in the future.
出处
《中华微生物学和免疫学杂志》
CAS
CSCD
北大核心
1998年第3期186-188,共3页
Chinese Journal of Microbiology and Immunology
基金
联合国开发计划署/世界银行/世界卫生组织热带病研究和培训特别规划署(TDR)的资助
关键词
核酸疫
裂殖子表面蛋白
基因表达
疟原虫
Nucleic acid vaccine
Merozoite surface protein 1
Gene expression\ \ Plasmid
Plasmodium falciparum
